药理干预措施对帕金森病中步行障碍的特定阶段疗效
Jun Zhang1,2, Le Chen1, Jun Li1
1Department of Neurology, Beijing Tsinghua Changgung Hospital, School of Clinical Medicine, Tsinghua Medicine, Tsinghua University, Beijing, China.
Frontiers in neurology
|October 31, 2025
概括
帕金森病 (PD) 的步态变化随着病情的进展而恶化. 利沃多巴药物可以改善步态,特别是在晚期,为PD进展提供了一个新的诊断标志物.
科学领域:
- 神经学 神经学
- 生物医学工程 生物医学工程
- 运动障碍 运动障碍
背景情况:
- 帕金森病 (PD) 是一种神经退行性疾病,影响运动控制.
- 步态障碍是PD的常见和使人虚弱的症状.
- 了解步态变化和药物效应对于PD管理至关重要.
研究的目的:
- 分析帕金森病不同阶段的步态特征.
- 评估药物对与PD相关的行走障碍的治疗效果.
- 根据步态分析,识别潜在的PD早期诊断标志物.
主要方法:
- 对60名PD患者 (Hoehn-Yahr阶段1-4) 和30名健康对照进行前性研究.
- 使用ReadyGo系统对目标步态参数进行记录.
- 给药的乐伏多巴挑战测试,以评估药物反应.
主要成果:
- 与对照组相比,PD患者的步伐长度,步伐高度和步伐速度显著减少,步伐时间和转时间增加.
- 步行参数显示,随着Hoehn-Yahr阶段的增加,步行参数逐渐下降.
- 莱沃多巴的使用导致了步伐速度和回转时间的显著改善,特别是在晚期PD阶段 (H-Y阶段3).
结论:
- 步态变化,特别是步伐速度和时间的变化,可以作为帕金森病的早期诊断标记.
- 目标步态监测可以跟踪PD的进展.
- 药物治疗虽然不像对震或度那么有影响,但在PD患者中有效改善了步态,特别是那些患有晚期疾病的人.
更多相关视频
相关概念视频
01:24Parkinson's Disease: Treatment
931
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
931
01:15Parkinson's Disease: Overview
1.7K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
1.7K